SCHEMBL5038607

SCHEMBL5038607

O=C(O)/C=C/c1cn(Cc2ccccc2)c2ccccc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.67
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
ALDH1A1 P00352 2/20 0.64
HTT P42858 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
CYP1A2 P05177 1/20 0.64
HSP90AA1 P07900 1/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2D6 P10635 1/20 0.64
MAPT P10636 1/20 0.64
CYP2C9 P11712 1/20 0.64
CYP2C19 P33261 1/20 0.64
ATM Q13315 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
DNTT P04053 1/20 0.64
SNCA P37840 4/20 0.59
POLB P06746 1/20 0.59
APP P05067 4/20 0.59
SENP7 Q9BQF6 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5038610 1.00 BACE1 (0.67) BACE1MEN1KMT2AALDH1A1HTT
SCHEMBL8169410 0.92 DNTT (0.62) BACE1MEN1KMT2AALDH1A1HTT
SCHEMBL8169407 0.92 DNTT (0.62) BACE1MEN1KMT2AALDH1A1HTT
SCHEMBL10624957 0.90 SNCA (0.62) BACE1MEN1KMT2AALDH1A1HTT
SCHEMBL10624962 0.90 SNCA (0.62) BACE1MEN1KMT2AALDH1A1HTT
SCHEMBL3220639 0.90 BACE1 (0.81) BACE1MEN1KMT2AALDH1A1HTT
SCHEMBL3220655 0.90 BACE1 (0.81) BACE1MEN1KMT2AALDH1A1HTT
SCHEMBL7706293 0.87 BACE1 (0.70) BACE1MEN1KMT2AALDH1A1HTT
SCHEMBL15486131 0.85 MEN1 (0.61) BACE1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL15486133 0.85 MEN1 (0.61) BACE1MEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2800748-B1 CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2017-03-29 EP disclosed
US-9453014-B2 Cyclic amide derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase and uses thereof CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) 2016-09-27 US disclosed
US-20150158860-A1 CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) 2015-06-11 US disclosed
US-8906952-B2 Indole derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic diseases containing same as active ingredient KOREA RESEARCH INSTITUTE OF BIOSCIENCE & BIOTECHNOLOGY (KR) 2014-12-09 US disclosed
US-20140057909-A1 Novel Indole Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Thereof, and Pharmaceutical Composition for Preventing or Treating Metabolic Diseases Containing Same as Active Ingredient KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2014-02-27 US disclosed
US-20080275153-A1 UV curable resin, its preparation and composition containing the same CHANG CHUN PLASTICS CO., LTD. (TW) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158860-A1 CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF HSD11B1, HSD11B2, HSD17B1 BACE1 860/4885MEN1 3676/4885KMT2A 2000/4885
US-20140057909-A1 Novel Indole Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Thereof, and Pharmaceutical Composition for Preventing or Treating Metabolic Diseases Containing Same as Active Ingredient DGAT2, DGAT1, DLAT BACE1 3392/4885MEN1 3352/4885KMT2A 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.